Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation

Background and Purpose- We compared the 1-year safety and effectiveness of rivaroxaban 15 mg (R15) or rivaroxaban 20 mg (R20) to vitamin K antagonists (VKAs) in patients with nonvalvular atrial fibrillation. Methods- New user cohort study of patients dispensed R15 or R20 versus VKA in 2013 or 2014 f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Stroke (1970) 2019-09, Vol.50 (9), p.2469-2476
Hauptverfasser:	Blin, Patrick, Fauchier, Laurent, Dureau-Pournin, Caroline, Sacher, Frédéric, Dallongeville, Jean, Bernard, Marie-Agnès, Lassalle, Regis, Droz-Perroteau, Cécile, Moore, Nicholas
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Aged, 80 and over Anticoagulants - therapeutic use Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Cardiology and cardiovascular system Cohort Studies Embolism - epidemiology Factor Xa Inhibitors - therapeutic use Female Fibrinolytic Agents - therapeutic use Hemorrhage - complications Human health and pathology Humans Life Sciences Male Pharmaceutical sciences Pharmacology Rivaroxaban - therapeutic use Santé publique et épidémiologie Stroke - drug therapy Stroke - epidemiology Vitamin K - antagonists & inhibitors Warfarin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!